An ST2‐dependent role of bone marrow‐derived group 2 innate lymphoid cells in pulmonary fibrosis by Zhao, Yuyue et al.
Journal of Pathology
J Pathol 2018; 245: 399–409
Published online 5 June 2018 in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.5092
ORIGINAL PAPER
An ST2-dependent role of bone marrow-derived group 2 innate
lymphoid cells in pulmonary fibrosis
Yuyue Zhao1, Francina Gonzalez De Los Santos2, Zhe Wu2, Tianju Liu2* and Sem H Phan2*
1 Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, China
2 Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
*Correspondence to: Tianju Liu, MD, PhD, 4830 BSRB, Department of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place,
Ann Arbor, MI 48109, USA. E-mail: tianliu@umich.edu;
Or Sem H Phan, MD, PhD, 4069 BSRB, Department of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI
48109, USA. E-mail: shphan@umich.edu
Abstract
Recent evidence supports that bone marrow (BM)-derived hematopoietic progenitor cells play an important role in
lung injury and fibrosis. While these cells give rise to multiple cell types, the ST2 (Il1rl1)-expressing group 2 innate
lymphoid cells (ILC2s) derived from BM progenitors have been implicated in tissue repair and remodeling, including
in lung fibrosis. To further investigate the precise role of BM-derived ILC2s in the pathogenesis of fibrotic lung
disease, their importance in the bleomycin-induced lung fibrosis model was evaluated by analyzing the effects
of selective ST2 deficiency in the BM compartment. The results showed that while ST2-sufficient control mice
exhibited activation of lung IL-33/ST2 signaling, ILC2 recruitment, IL-13 induction, and fibrosis, these responses
were significantly diminished in ST2-deficient-BM chimera mice, with selective loss of ST2 expression only in the
BM. This diminished response to bleomycin was similar to that seen in ST2 global knockout mice, suggesting
the predominant importance of ST2 from the BM compartment. In wild-type mice, ILC2 recruitment to the
lung was accompanied by a concomitant decrease in ST2+ BM cells. ST2-deficient BM cells were unresponsive
to IL-33-induced ILC2 maturation. Finally, lineage-negative wild-type, but not ST2-deficient BM cells from
bleomycin-treated mice stimulated lung fibroblast type I collagen expression, which was associated with elevated
TGF expression in the BM cells. Taken together, these findings suggested that the BM-derived ILC2s were recruited
to fibrotic lung through the IL-33/ST2 pathway, and contributed to fibroblast activation to promote lung fibrosis.
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Introduction
Pulmonary fibrosis is a common end result of multiple
insults to the lung [1]. Idiopathic pulmonary fibrosis
(IPF) is the most common fibrotic interstitial lung
disease of uncertain etiology with a poor prognosis
[2]. A growing body of evidence suggests the impor-
tance of bone marrow (BM)-derived cells in animal
model studies [3–6]. BM-derived lung hematopoietic
progenitor cells rapidly migrate into the lung after
injury, and subsequently contribute to fibrogenesis
in a paracrine manner [4]. Moreover, BM CD11c+
cell-derived amphiregulin promotes pulmonary fibrosis
[7]. ST2-expressing group 2 innate lymphoid cells
(ILC2s) represent another source of amphiregulin [8,9],
and they have been implicated in fibrosis by studies ana-
lyzing the effects of deficiency of ST2 (Il1rl1) [10–12].
However, these studies cannot rule out the importance
of ST2 in other (non-ILC2) cell types.
The ST2 ligand IL-33 is important for innate mucosal
immunity in the lung and gut [13,14], and is also
implicated in multiple pathogenic processes such as
inflammation, tissue repair/fibrosis, and scleroderma
[10,15–17]. It is expressed by endothelial and type II
alveolar epithelial cells in the lung [13,14,16]. Its recep-
tor ST2 is also widely expressed on multiple cell types
including Th2 cells, mast cells, Th1 cells, regulatory T
(Treg) cells, CD8+ T cells, natural killer (NK) cells, and
group 2 innate lymphoid cells (ILC2s) [18]. ST2 (Il1rl1)
pre-mRNA produces four isoforms through alternative
splicing: ST2L, soluble ST2 (sST2), ST2V, and ST2LV
[19]. ST2L is expressed on the membrane of hematopoi-
etic cells [20], whereas sST2 is predominantly expressed
by fibroblasts and epithelial cells functioning as a decoy
receptor that exhibits anti-inflammatory properties [21].
ST2-expressing ILC2s represent important effector cells
in the host response to infection, wound remodeling,
allergic responses, fat biogenesis, and obesity [22–25].
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ILC2s accumulate in tissue during type 2 inflammation,
and function as a main source of cytokines such as
IL-13, IL-4, IL-5, and amphiregulin [8,22,26–28],
which are implicated in the process of tissue repair
and fibrosis [7,29,30]. Both ST2 and IL-33 levels are
induced in murine bleomycin (BLM)-induced pul-
monary fibrosis and human IPF, and increased numbers
of lung ILC2s are associated with fibrosis in the mouse
[10,31,32]. Moreover, adoptive transfer of lung ILC2s
enhances fibrosis in recipient mice, whereas anti-IL-33
antibodies or ST2 deficiency diminishes fibrosis [10].
These findings, along with association with alternative
activation of macrophages (M2), suggest important
roles for both ILC2s and M2 macrophages in fibro-
sis. However, that previous study relied on systemic
antibody treatment or global ST2 knockout mice; thus,
the diminished fibrosis cannot be attributed solely to
ILC2s in view of the multiplicity of cell types that
express ST2 and are IL-33 responsive. Furthermore,
while the ILC2 adoptive transfer study indicates the
ability of exogenous ILC2s to enhance fibrosis, it does
not necessarily reveal a role for endogenous ILC2s in
pathogenesis, nor does it give insight into the origin of
lung ILC2s in pulmonary fibrosis.
In this study, we hypothesized the BM origin and
paracrine role of ILC2 in BLM-induced lung fibrosis.
To assess potential BM origin, we used ST2-deficient
BM chimera mice lacking ST2 expression only in the
BM and resulting in deficiency of BM-derived ILC2
because IL-33/ST2 signaling is essential for ILC2 dif-
ferentiation/activation [24,33,34]. The results revealed
that BLM-induced expansion of the lung ILC2 popula-
tion and fibrosis was virtually abrogated in ST2-deficient
BM chimera mice. Control lung ST2 expression and
ILC2s were not affected by BM transplantation with
ST2-deficient BM. In vitro cell co-culture studies sug-
gested paracrine regulation of myofibroblast differen-
tiation by the BM-derived ILC2s, which if adequately
amplified could serve as a potential mechanism by
which ILC2s could promote fibrosis. These findings sug-
gested that in response to a distal lung insult, ILC2s
were recruited from the BM and activated/differentiated
through IL-33/ST2 signaling, and in association with
M2 macrophage differentiation contributed to fibroblast
activation to promote the development of lung fibrosis
in an ST2-dependent manner.
Materials and methods
Mice and bleomycin model of pulmonary fibrosis
C57BL/6 female mice (6–8 weeks of age) were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA).
ST2 knockout (KO) mice on a C57BL/6 background
were from Dr Stefan Wirtz (Friedrich Alexander Uni-
versität Erlangen, Erlangen, Germany). All mice were
housed in the University Laboratory Animal Facility
under animal protocols approved by the Institutional
Animal Care and Use Committee at the University of
Michigan. The lung fibrosis model was induced by the
endotracheal instillation of 2 U/kg BLM (Blenoxane;
Mead Johnson, Princeton, NJ, USA) as described pre-
viously [3]. Control mice received the same volume of
PBS only. ST2 KO BM chimera mice were generated by
transplanting donor ST2 KO BM cells into recipient WT
mice as described previously [3]. Mice receiving WT
donor BM cells were used as controls [3]. The chimera
mice were maintained on acidified water and autoclaved
feed ad libitum for 6 weeks before use in the fibrosis
model as described above.
Collection of bronchoalveolar lavage fluid
Bronchoalveolar lavage (BAL) was performed using
0.5 ml of PBS and repeated three times for collection of
BAL fluid. BAL fluid was then centrifuged at 500× g for
10 min to pellet cells. Total protein was measured using a
Pierce BCA protein assay kit (Thermo Fisher Scientific,
Rockford, IL, USA).
Cell isolation
Single cell suspensions of lung cells for flow cytometry
and primary mouse lung fibroblasts were isolated and
cultured as described previously [3,35].
Lineage-negative (Lin−) BM cells were isolated
from whole BM cell suspension using a mouse lineage
cell cocktail kit (Miltenyi Biotec Inc, San Diego, CA,
USA). Where indicated, isolated cells were treated with
30 ng/ml recombinant mouse IL-33 (R&D Systems,
Minneapolis, MN, USA) for 48 h. For cell co-culture
experiments, normal lung fibroblasts were plated (8 ×
10[4] cells per well) in the bottom chambers of 24-well
Transwell plates with 0.4 μm-pore polycarbonate mem-
brane inserts (Thermo Fisher Scientific) for 24 h. The
cells were starved in serum-free medium for another
24 h, followed by the addition of 1.5 × 10[6] Lin−
BM cells from WT or ST2 KO mice treated with PBS
or BLM to the upper inserts. After an additional 24 h
of incubation, the fibroblasts were collected for RNA
isolation.
Reverse transcription–PCR (RT-PCR) and ELISA
RNA isolation and RT-PCR were performed as
described previously [35]. Primers for assessing the
mRNA levels for IL-33 (Il33), ST2L, type I collagen
(Col1a2), Acta2, TGFβ (Tgfb1), IL-13 (Il13), amphireg-
ulin (Areg), TNFα (Tnf ), Arg1, Nos2, and 18S rRNA
were purchased from Thermo Fisher Scientific. Results
were expressed as 2−ΔΔCT using the indicated control
group as calibrator and 18S rRNA as reference 36.
Soluble ST2 (sST2) levels in BAL fluid from control
and BLM-treated mice and media from cell co-cultures
were detected using an ST2 ELISA kit (R&D Systems)
in accordance with the manufacturer’s instructions.
Hydroxyproline and histological analysis
Lung collagen content was determined by measuring
the hydroxyproline content from lung homogenates as
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described previously [35]. The results were expressed
as μg hydroxyproline per lung. The lung sections were
stained with H&E or Masson’s trichrome for evaluation
of histopathology.
Flow cytometry
Single cell suspensions from freshly digested lung
tissue or BM were prepared as described above and
analyzed by flow cytometry as described previously
[37]. Dead cells were excluded from analysis using
the Fixable Viability Dye eFluor™ 506 (#65-0866;
dilution 1:1000; eBioscience, San Diego, CA, USA).
Combinations of the following antibodies (and flu-
orophores) were used: anti-mouse ST2-PE-Cy7
(#25-9335-80, clone: RMST2-2; dilution 1:100; eBio-
science), IL-13-Alexa Fluor 488 (#53-7133-82, clone:
eBio13A; 1:100; eBioscience), ICOS-BV421 (#564070,
clone: 7E.17G9; 1:100; BD Biosciences, San José, CA,
USA), Lineage-APC cocktail of anti-CD3e, CD11b,
B220, TER-119, Ly-6C, Ly-6G (#558074; 1:5; BD Bio-
sciences), CD90.2-APC-Cy7 (#105732, clone: 30-H12;
1:100; Biolegend, San Diego, CA, USA), CD45-Pacific
Blue (#103126, clone: 30-F11; 1:200; Biolegend),
along with their respective isotype controls. The data
were acquired using a NovoCyte flow cytometer and
analyzed by NovoExpress software (Aeca Biosciences,
Inc, San Diego, CA, USA). All other fluorescence
conjugated-antibody controls except the target antibody
were used for compensation.
Statistical analysis
All data are presented as mean values ±SEM. Differ-
ences between any two groups were assessed for sta-
tistical significance by ANOVA followed by post hoc
analysis using Scheffé’s test. A P value less than 0.05
was considered to be statistically significant.
Results
Effects of selective BM ST2 deficiency on lung ILC2
induction and pulmonary fibrosis
To study the involvement of the IL-33/ST2 signaling
pathway and ILC2 in BLM-induced pulmonary fibro-
sis, we first confirmed that lung Il33 and ST2 mRNAs
were highly induced at days 7 and 21 after BLM treat-
ment (Figure 1A, B). The protein level of sST2 in BAL
fluid was significantly induced at days 7 and 21 after
BLM treatment (Figure 1C) but not in plasma (data
not shown). Flow cytometry analysis revealed a signif-
icant increase in Lin−CD45+CD90.2+ST2+ ILC2s in
BLM-injured lung at day 7 (Figure 1D), which was sus-
tained at day 21 after BLM treatment (data not shown).
To exclude the contribution of ST2 in endogenous
lung cell types and assess the specific importance of
BM-derived ILC2s, we evaluated the in vivo effects
of selective ST2 deficiency in BM progenitors using
ST2 KO BM chimera mice. Since ILC2s are devel-
opmentally derived from the BM [34,38,39] with a
dependence on IL-33/ST2 signaling for their differ-
entiation/activation and recruitment to distal organs
[24,33,34], this approach has been used as a means to
assess the importance of BM-derived ILC2s. Indeed,
flow cytometric analysis revealed that lung ILC2s were
markedly reduced in ST2 KO chimera mice due to
a lack of ST2 in BM cells (Figure 2A, B), without
significantly affecting differentiated (Lin+/CD45+
cells) myeloid cells (10.2±1.9 versus 11.09±2.23 as
% of total lung cells in control versus ST2 KO BM
chimera mice, respectively) or CD11chi/MHCIIhi cells
(0.83±0.17 versus 1.15±0.01% of total lung cells in
WT versus BM ST2 KO BM chimera mice, respec-
tively) in the lungs of BLM-treated mice. Notably, the
BLM-induced increase in lung ILC2s in WT mice was
essentially abolished in ST2 KO BM chimera mice,
which was accompanied by a significant reduction in
BLM-induced Il13 levels in ST2 KO BM chimera mice
(Figure 2C). Thus, ST2 expression in BM progenitor
cells was essential for recruitment/activation of lung
ILC2s and IL-13 induction in pulmonary fibrosis.
Next, we investigated the impact of BM ST2 defi-
ciency on pulmonary fibrosis. BLM induced extensive
fibrosis in WT mouse lungs but it was attenuated and
more circumscribed in the lungs of ST2 KO BM chimera
mice (Figure 2D), which was accompanied by reduced
deposition of collagen in ST2 KO BM chimera lungs, as
shown by Masson’s trichrome staining (supplementary
material, Figure S1). This reduced fibrosis was con-
firmed quantitatively by a significant reduction in lung
collagen content (Figure 2E) and Col1a2 mRNA lev-
els (Figure 2F). Significant inhibition of BLM-induced
myofibroblast differentiation was also noted, as assessed
by Acta2 expression (Figure 2F). Additionally, the
induction of Tnfa and Tgfb1 was also inhibited in ST2
KO BM chimera lung after BLM treatment (Figure 2G).
Finally, the BLM-induced increase in M2 marker Arg1
mRNA in WT controls was significantly reduced in
ST2 KO BM chimera mice at day 7 but not at day 21
(Figure 2H). No significant effect was noted in the
induction of the M1 marker Nos2 (data not shown).
These findings together suggested that the BM ST2 defi-
ciency prevented ILC2 recruitment/activation and early
M2 polarization, which was accompanied by subsequent
impairment of BLM-induced pulmonary fibrosis.
Given that the absence of ST2 expression was selec-
tively confined to the BM compartment, this would sug-
gest that the expansion in lung ILC2s in response to
BLM-induced lung insult in WT mice might be due to
IL-33/ST2-dependent recruitment of ILC2s or ILC2 pre-
cursors from the BM, as previously shown [34,38–40].
Flow cytometric analysis revealed that the number of
ST2+ cells was increased more than three-fold in the
lung after BLM treatment (Figure 3A). In contrast, ST2+
BM cells were significantly decreased after BLM treat-
ment, which would be consistent with recruitment of
these cells to the lung, resulting in their depletion in
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Figure 1. Effects of BLM on lung IL-33 and ST2 expression, and ILC2 cell number. Lung tissue RNA samples from BLM- or PBS-treated
mice at days 7 and 21 after treatment were analyzed for Il33 (A) or ST2 (Il1rl1) (B) mRNA levels by RT-qPCR. N = 3 mice per group. In C,
soluble ST2 protein levels in BAL fluid from BLM- or PBS-treated mice were quantified by ELISA (N = 3–8). In D, whole lung single cell
suspensions were prepared 7 days after BLM treatment. ILC2s were gated as lineage-negative (Lin−) CD45+ST2+CD90.2+. The cells were
first gated on Lin−CD45+ and then analyzed for ST2 and CD90.2 expression for enumeration of ILC2s shown as a percentage of total cells.
Data are shown as mean±SE. *p < 0.05 between the two groups indicated in A–C. The experiments were independently repeated twice,
and a representative data set is shown.
the originating BM. Since IL-33 is the cognate lig-
and for ST2, the response of ST2-deficient BM cells
to IL-33 was evaluated to confirm its importance in
ILC2 activation/differentiation. The results showed that
while ILC2s were highly induced by IL-33 in WT
Lin− BM cells, ST2-deficient cells failed to respond
(Figure 3B). Thus, BM ST2+ ILC2s or their progenitors
were recruited to the lung in an IL-33/ST2-dependent
manner and accounted for the expansion of lung ILC2s
in BLM-induced pulmonary fibrosis.
Comparative role of BM versus lung ST2 expression
in BLM-induced pulmonary fibrosis
To evaluate the relative importance of BM versus lung
IL-33/ST2 signaling in vivo, BLM-induced lung fibro-
sis was also evaluated in WT and global ST2 KO mice.
Compared with WT mice, ST2 KO mice showed reduced
BLM-induced lung fibrosis morphologically, with a
smaller and less diffuse distribution of fibrotic lesions
(Figure 4A), which was accompanied by a significant
reduction in the BLM-induced increase of lung Col1a2
(Figure 4B) and Acta2, a myofibroblast differentiation
marker (Figure 4C). This reduction in BLM-induced
pulmonary fibrosis in globally ST2-deficient mice was
comparable to that seen in mice deficient in ST2 expres-
sion restricted to the BM compartment (Figure 2D, E).
Flow cytometric analysis of the lung cells revealed
that the significant increase in lung ILC2s after BLM
treatment also markedly reduced in global ST2 KO
mice (Figure 5A), which was also comparable to that
seen in mice with ST2 deficiency restricted to the BM
(Figure 2B). This was accompanied by significantly
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Figure 2. BLM-induced lung ILC2 recruitment and pulmonary fibrosis were abrogated in ST2 KO BM chimera mice. Lung cell suspensions
from BLM- or PBS-treated WT (receiving WT BM) or ST2 KO BM chimera (receiving ST2 KO BM) mice at day 21 after treatment were analyzed
for ILC2s as in Figure 1. A representative plot set is shown in A, and a summary from three separate experiments is shown in B. Data are
shown as mean± SE. N = 3. *p < 0.05 between the two groups indicated. (C) Lung Il13 mRNA was analyzed from BLM- or PBS-treated ST2
KO BM chimera lung at day 21 after treatment. Data are shown as mean± SE. N = 3 mice per group. *p < 0.05 between the two groups
indicated. (D) Representative lung tissue sections from WT or ST2 KO BM chimera mice treated as described in A were stained with H&E
(original magnification×40). (E) Lung tissue samples were evaluated for collagen content by hydroxyproline assay. (F) Lung tissue mRNA
levels of type I collagen (Col1a2) and α-SMA (Acta2). Tnfa and Tgfb1 (G), as well as the M2 macrophage marker Arg1 (H), were analyzed
by RT-qPCR. Data are shown as mean± SE. N = 5 mice per group. *p < 0.05 between the two groups indicated.
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Figure 3. Effects of BLM on lung and BM ST2+ cells and ILC2 response to IL-33. (A) Lung and BM cells from BLM- or PBS-treated mice were
analyzed for ST2 expression by flow cytometry, and the absolute numbers of ST2+ cells are shown. Data are shown as mean± SE. N = 3.
*p < 0.05 between the two groups indicated. (B) Lin− BM cells isolated from WT or ST2 KO mice were treated with 30 ng/ml IL-33 in vitro
and then analyzed for ILC2 by flow cytometry. A representative scatter plot is shown. N = 3 per group.
decreased numbers of IL-13-expressing ILC2s in
BLM-treated ST2-deficient mice (Figure 5A). BLM
induction of both lung IL-13 and amphiregulin expres-
sion was also reduced in ST2-deficient mice (Figure 5B,
C). The reduction in lung Il13 levels in global ST2 KO
mice (Figure 5B) was also similar to that in mice lack-
ing ST2 only in the BM (Figure 2C). These findings
indicated that ST2 deficiency impaired the recruit-
ment/activation and function of ILC2s in BLM-induced
lung fibrosis, and that ST2 expression in the BM
compartment was of predominant importance in the
BLM-induced expansion of lung ILC2s and fibrosis.
BM-derived ILC2s activated lung fibroblasts
by increasing collagen I expression
To elucidate the possible mechanism by which
BM-derived ILC2s promoted lung fibrosis, we evalu-
ated the effect of isolated BM-derived ILC2s on lung
fibroblast activation. As only very few ILC2s could be
isolated from mouse lungs, we used the more abun-
dant Lin− BM cells to assess possible effects on lung
fibroblast activation. These Lin− BM cells consisted
of progenitor cells as well as ILC2s, and were used in
co-cultures with normal lung fibroblasts. The results
showed that Lin− BM cells isolated from BLM-treated
WT mice caused a significant increase in Col1a2 levels
in lung fibroblasts, relative to BM cells from control
PBS-treated mice (Figure 6A). However, BM cells
from BLM-treated ST2 KO mice fibroblasts, compared
with PBS-treated controls, failed to stimulate Col1a2
levels. Interestingly, the Lin− BM cells isolated from
BLM-treated WT mice expressed significantly higher
levels of Tgfb1 relative to cells from WT PBS controls
(Figure 6B), which was abrogated in BM cells from
ST2 KO mice. This suggested that induction of TGFβ
in BM progenitors and/or ILC2s could have caused the
noted effects on fibroblast activation. This induction of
TGFβ was likely due to BLM-induced IL-33, since it
was dependent on ST2, and thus supported the identifi-
cation of the Lin− BM cell as a likely ILC2 progenitor.
Taken together, these findings would be consistent
with BLM-induced lung IL-33 as an important signal
for BM progenitor/ILC2 activation to enhance TGFβ
expression leading to the activation of lung fibroblasts
after BM-derived ILC2 recruitment to the lung.
Discussion
Innate lymphoid cells (ILCs) are recently discovered
immune cells that reside at epithelial barriers such as
the lung, skin, and gut, and contribute to immunity,
inflammation, tissue homeostasis, and repair processes
following exposure to allergens, pathogens or chemical
irritants [41–43]. Three subsets of ILCs produce differ-
ent type of cytokines. ILC2s produce type 2-associated
cytokines, including IL-4, IL-5, and IL-13, as well as
amphiregulin, thus playing important roles in parasite
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Figure 4. BLM-induced pulmonary fibrosis was attenuated in ST2 KO mice. WT or ST2 KO mice were treated with BLM or PBS endotracheally.
Pulmonary fibrosis was evaluated at day 21 after treatment by histopathology (A; representative tissue section shown; ×40 objective
magnification). Col1a2 (B) and Acta2 (C) mRNA levels. Data are shown as mean± SE. n= 3–5. *p < 0.05 between the two groups indicated.
The experiments were independently repeated twice, and a representative data set is shown.
Figure 5. Lung ILC2 recruitment and activation were ablated in ST2 KO mice. Whole lung single cell suspension were prepared from day
7 PBS- or BLM-treated WT or ST2 KO lungs, and analyzed for ILC2s by flow cytometry and Il13 expression in ILC2s. (A) The absolute cell
numbers per lung are shown for ILC2s and IL-13+ ILC2s. N = 3 mice per group. Lung RNA samples from BLM- or PBS-treated mice were
analyzed for IL-13 (B) or amphiregulin (Areg) (C) mRNA levels by RT-qPCR. N = 3 mice per group. Data are shown as mean± SE. *p < 0.05
between the two groups indicated.
immunity, allergic inflammation, and tissue homeostasis
and fibrosis [23,24,26,44,45]. The ST2 ligand, IL-33, is
a potent inducer of ILC2 activation [8,16]. The present
study provided evidence that the IL-33/ST2 signaling
pathway was induced in a model of lung injury and fibro-
sis through which the ILC2s were recruited from the BM
and activated in the injured lung to promote fibrosis, per-
haps by activating lung fibroblasts via TGFβ.
IL-33 induction was also found in the BAL fluid
in patients with IPF [46]. The elevated sST2 level in
the BAL fluid in BLM-induced lung fibrosis was also
consistent with activation of the IL-33/ST2 signaling
pathway in lung fibrosis. The basis for this activation
of ST2 signaling in pulmonary fibrosis may be due to
the induction of IL-33 in injured epithelial cells serving
as an alarm signal. Elevated sST2 in BAL fluid, but
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Figure 6. Lung fibroblasts were activated by BM-derived progenitor
cells from BLM-treated mice. (A) Normal lung fibroblasts were
co-cultured with Lin− BM cells isolated from BLM- or PBS-treated
WT or ST2 KO mice 21 days after treatment. Fibroblast Col1a2 was
analyzed by RT-qPCR. In B, similarly isolated Lin− BM cells from the
same groups of mice were analyzed for Tgfb1 mRNA by RT-qPCR.
Data are shown as mean± SE. N = 5 mice per group. *p < 0.05
between the two groups indicated.
not in plasma, during lung fibrosis was sustained until
the late stage of fibrosis at day 21. As an endogenous
decoy receptor of IL-33, sST2 also antagonizes IL-33
and inhibits the IL-33/ST2L-induced Th2 response, and
exogenous sST2 administration reduces BLM-induced
fibrosis [47–49]. The significance of this induction of
sST2 is unclear, given its paradoxical inhibitory effect
on IL-33–ST2 signaling. It may be that the site of sST2
secretion occurs at a different location to where IL-33 is
released from damaged cells. Further studies are needed
to investigate the precise role of sST2.
The increase in IL-33-responsive ILC2s is not
unique to animal models of pulmonary fibrosis as
they are also increased in systemic sclerosis, corre-
lating with the extent of fibrosis [50,51]. They are
also present in the BAL samples and lung tissue of
patients with IPF, wherein they are associated with
upregulated expression of lung IL-33 and IL-25 [23,52].
The IL-33/ST2-induced increase in ILC2 number in
BLM-induced lung fibrosis was ST2-dependent, as
the ILC2 number and fibrosis were reduced in ST2
KO mice after BLM treatment. This is an expected
finding given the dependence of ILC2 development
on IL-33/ST2 signaling [24,33,34]. These findings are
in agreement with another study where BLM-induced
fibrosis was attenuated in global ST2 KO or by neutral-
izing IL-33 systemically through possible inhibition of
M2 macrophage polarization [10]. Moreover, fibrosis is
enhanced by adoptive transfer of ILC2s, although this
does not indicate a requirement for endogenous ILC2s
in fibrosis. Although BM ST2 deficiency also reduced
M2 polarization, IL-33 alone cannot induce polarization
[10]. While IL-13 alone can induce M2 polarization
even in the absence of ST2, the addition of IL-33 mag-
nifies this response [10,53]. This essential requirement
for IL-13 to enable IL-33-induced polarization is due
to the induction of ST2 by IL-13 [53]. Thus, it is likely
that the induction of IL-13 in recruited ILC2s precedes
and is essential for the subsequent enhanced M2 polar-
ization by IL-33 [10,54]. IL-33-induced ILC2s are also
an important source of IL-13 in liver fibrosis via the
ST2-dependent signaling pathway [12], which would
be consistent with the reduction in IL-13 expression in
ST2-deficient mice in the BLM model of pulmonary
fibrosis, thus impacting negatively on M2 polarization
as noted.
However, studies using ST2 KO mice or antibodies
to IL-33 cannot exclude impairment of IL-33/ST2 sig-
naling in cells other than ILC2s as ST2 is expressed
by diverse cell types [19]. To analyze more specifi-
cally the contribution of ILC2s in pulmonary fibrosis,
we restricted the ST2 deficiency to the BM compart-
ment by transplanting donor ST2 KO BM into WT
recipients. Given that ILC2s originate developmentally
from the BM and given their dependence on IL-33 (via
ST2) for their development, this approach has been
used as a means of depleting ILC2s [12,34,55]. Previ-
ously, ILC2s arising from BM progenitors were shown
to migrate into lung in response to parasitic infection
or allergic stimulation [33,34,56]. Using the ST2 KO
BM chimera mice in this study, we provided evidence
that lung ILC2 development, recruitment, and activation
were dependent on ST2 expression on the BM progen-
itor, and Lin− BM cells lacking ST2 expression failed
to respond to IL-33 stimulation. Although this study
did not completely exclude the potential impact of ST2
deficiency on other BM ST2-expressing cell types and
their role(s) in fibrosis, there is evidence that ST2 defi-
ciency has no significant impact on T-cell, mast cell, or
lung macrophage development/function, or host defense
against mycobacterial infection [10,57,58], consistent
with a unique dependence of ILC2 differentiation on
IL-33/ST2 signaling. Moreover, IL-33 overexpression
in the BM has no significant impact on the number of
eosinophils, neutrophils, basophils or M2 macrophages
in the BM [59]. Other studies have used similar BM
chimera strategies but using RORα-deficient BM donor
cells to deplete ILC2s, which showed a similar lack of a
significant effect on T cells [60].
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Our results also revealed that ST2 KO BM chimera
mice developed significantly decreased lung fibrosis
and myofibroblast differentiation. These findings sug-
gested that IL-33, as a signal, released from injured
lung epithelial cells [16] initiated BM-derived ILC2
recruitment, development, and activation through the
IL-33/ST2 signaling pathway with subsequent pro-
motion of pulmonary fibrosis. Indeed, a recent study
showed that ST2-dependent IL-33 signaling is a critical
component in promoting egress of ILC2s from the BM
in response to exogenous IL-33 administration, distal
tissue depletion of ILC2s or fungal infection [34]. In
our current study, the source of IL-33 was from the
BLM-injured lung, and similar to this other recent study
[34], deficiency of ST2 in the BM cells abrogated the
response to the IL-33 from the lung. Other studies also
provide support to the BM origin of ILC2s, especially
under prolonged injury or disruption of homeostasis in
tissues [34,40,61–64]. In our current study, the irradia-
tion and BM transplantation procedure did not cause a
significant change in the endogenous lung ILC2 popula-
tion after stable engraftment was achieved (Figures 2B
and 5C), suggesting that only the BLM insult-induced
expansion in lung ILC2s was recruited from the BM,
likely in response to the associated induction of lung
IL-33 expression. Another recent study suggests the
small intestine as an alternative site of origin for a
subset of lung inflammatory ILC2s (iILC2s) [40]. Small
intestine iILC2 precursors, not endogenous lung cells,
migrate to the lung and give rise to proliferating iILC2s
induced by IL-25 or helminth infection. However, it
is noteworthy that the BM ST2-dependent recruited
ILC2s in fibrotic lung with IL-33 induction in our
study exhibited a Lin−ST2+CD90.2+ phenotype, which
differed from the IL-25 or helminth infection-induced
lung Lin−KLRG1hiST2−CD90.2lo iILC2s [40], sug-
gesting that pulmonary fibrosis and acute helminth
infection-induced inflammation may induce/recruit
different ILC2 subsets potentially from different distal
organ sites of origin. The mechanism of ILC2 recruit-
ment appears to be IL-33/ST2-dependent in these and
our current studies, but may be subject to regulation
by additional agents, such as TGFβ, which has been
reported to enhance ILC2 chemoattractant activity [65].
The induction of IL-13 from recruited and acti-
vated ILC2s could account for their role in fibrogenesis
[12,29,30]; however, direct effects of ILC2s on fibrob-
last activation have not been fully investigated. In our
current study, an alternative paracrine role for ILC2s in
fibrosis was suggested by the studies using co-culture
of Lin− BM cells with lung fibroblasts. While ILC2s or
their precursors comprise only a fraction of the Lin− BM
cells used in this study, the dependence of the effects
on ST2 expression makes it likely that any observed
effects are due primarily to ILC2s and/or their precur-
sors. The findings revealed induction of ST2-dependent
TGFβ expression in BM cells in vivo in response to dis-
tal lung insult by BLM, perhaps caused by induction
of lung IL-33 with consequent effects on ILC2 differ-
entiation. This induction of TGFβ was associated with
activation of the co-cultured lung fibroblasts, as mani-
fested by increased collagen I expression. Such potential
crosstalk between activated BM-derived ILC2s and lung
fibroblasts via TGFβ could represent an additional novel
mechanism by which ILC2s could promote lung fibro-
sis. While the relative number of lung ILC2s is small, it
could have a disproportionately larger effect by ampli-
fication of paracrine effects in adjacent cells, including
M2 polarization and potentially other BM-derived cell
types known to play a role in fibrosis [3,4,7,37]. More-
over, TGFβ is known to be auto-inducible [66], such that
the effect of the initial release by activated ILC2s can
be amplified by auto-induction of greater levels of this
cytokine in the initial target and other adjacent cells.
Further studies are needed to fully explore the in vivo
relevance of these in vitro findings and put them in the
context of pulmonary fibrosis.
Acknowledgements
We thank Lisa R Riggs for excellent technical assistance
in the tissue section preparation and the H&E and Mas-
son’s trichrome staining. This study was supported by
NIH grants HL052285 and HL112880 (to SHP) and a
fellowship from The China Scholarship Council (to YZ).
Author contributions statement
YZ, TL, and SHP conceived experiments. YZ, FG, ZW,
and TL carried out experiments and collected data. YZ,
TL, and SHP analyzed data and wrote the manuscript.
All authors were involved in writing the paper and had
final approval of the submitted and published versions.
References
1. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology
and regulation. Mucosal Immunol 2009; 2: 103–121.
2. Raghu G, Rochwerg B, Zhang Y, et al. An Official
ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of
Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical
Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
3. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor
cells in pulmonary fibrosis. J Clin Invest 2004; 113: 243–252.
4. Nakashima T, Liu T, Yu H, et al. Lung bone marrow-derived
hematopoietic progenitor cells enhance pulmonary fibrosis. Am J
Respir Crit Care Med 2013; 188: 976–984.
5. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an
indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med 2009; 179: 588–594.
6. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector
cells in chronic inflammation. Nat Rev Immuol 2011; 11: 427–435.
7. Ding L, Liu T, Wu Z, et al. Bone marrow CD11c+ cell-derived
amphiregulin promotes pulmonary fibrosis. J Immunol 2016; 197:
303–312.
8. Monticelli LA, Osborne LC, Noti M, et al. IL-33 promotes an
innate immune pathway of intestinal tissue protection dependent on
amphiregulin–EGFR interactions. Proc Natl Acad Sci U S A 2015;
112: 10762–10767.
Copyright © 2018 Pathological Society of Great Britain and Ireland. J Pathol 2018; 245: 399–409
Published by John Wiley & Sons, Ltd. www.pathsoc.org www.thejournalofpathology.com
408 Y Zhao et al
9. Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and
IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp
Med 2013; 210: 2939–2950.
10. Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes
ST2-dependent lung fibrosis by the induction of alternatively
activated macrophages and innate lymphoid cells in mice. J Allergy
Clin Immunol 2014; 134: 1422–1432.e11.
11. Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces
IL-13-dependent cutaneous fibrosis. J Immunol 2010; 184:
1526–1535.
12. McHedlidze T, Waldner M, Zopf S, et al. Interleukin-33-dependent
innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39:
357–371.
13. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like
cytokine that signals via the IL-1 receptor-related protein ST2 and
induces T helper type 2-associated cytokines. Immunity 2005; 23:
479–490.
14. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of
innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010;
107: 18581–18586.
15. De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis:
role in health and disease. Cytokine Growth Factor Rev 2015; 26:
615–623.
16. Yasuda K, Muto T, Kawagoe T, et al. Contribution of IL-33-activated
type II innate lymphoid cells to pulmonary eosinophilia in intestinal
nematode-infected mice. Proc Natl Acad Sci U S A 2012; 109:
3451–3456.
17. Vettori S, Cuomo G, Iudici M, et al. Early systemic sclerosis: serum
profiling of factors involved in endothelial, T-cell, and fibroblast
interplay is marked by elevated interleukin-33 levels. J Clin Immunol
2014; 34: 663–668.
18. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and
disease. Nat Rev Immunol 2016; 16: 676–689.
19. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and
novel biomarker. Nat Rev Drug Discov 2008; 7: 827–840.
20. Yanagisawa K, Takagi T, Tsukamoto T, et al. Presence of a novel
primary response gene ST2L, encoding a product highly similar to
the interleukin 1 receptor type 1. FEBS Lett 1993; 318: 83–87.
21. Takagi T, Yanagisawa K, Tsukamoto T, et al. Identification of the
product of the murine ST2 gene. Biochim Biophys Acta 1993; 1178:
194–200.
22. Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid
cells promote lung tissue homeostasis following acute influenza virus
infection. Nat Immunol 2011; 12: 1045–1054.
23. Hams E, Armstrong ME, Barlow JL, et al. IL-25 and type 2 innate
lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A
2014; 111: 367–372.
24. Halim TY, Steer CA, Matha L, et al. Group 2 innate lymphoid cells
are critical for the initiation of adaptive T helper 2 cell-mediated
allergic lung inflammation. Immunity 2014; 40: 425–435.
25. Hams E, Locksley RM, McKenzie AN, et al. Cutting edge: IL-25
elicits innate lymphoid type 2 and type II NKT cells that regulate
obesity in mice. J Immunol 2013; 191: 5349–5353.
26. Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed
innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad
Sci U S A 2010; 107: 11489–11494.
27. Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25- and
IL-33-responsive type 2 innate lymphoid cells are defined by expres-
sion of CRTH2 and CD161. Nat Immunol 2011; 12: 1055–1062.
28. Califano D, Furuya Y, Roberts S, et al. IFN-γ increases susceptibility
to influenza A infection through suppression of group II innate
lymphoid cells. Mucosal Immunol 2018; 11: 209–219.
29. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. Interleukin
(IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma.
J Clin Invest 1998; 101: 2129–2139.
30. Lukacs NW, Hogaboam C, Chensue SW, et al. Type 1/type 2
cytokine paradigm and the progression of pulmonary fibrosis. Chest
2001; 120: 5S–8S.
31. Luzina IG, Kopach P, Lockatell V, et al. Interleukin-33 potentiates
bleomycin-induced lung injury. Am J Respir Crit Care Med 2013;
49: 999–1008.
32. Xu J, Zheng J, Song P, et al. IL-33/ST2 pathway in a
bleomycin-induced pulmonary fibrosis model. Mol Med Rep
2016; 14: 1704–1708.
33. Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells
mediate influenza-induced airway hyper-reactivity independently of
adaptive immunity. Nat Immunol 2011; 12: 631–638.
34. Stier MT, Zhang J, Goleniewska K, et al. IL-33 promotes the egress
of group 2 innate lymphoid cells from the bone marrow. J Exp Med
2018; 215: 263–281.
35. Liu T, Baek HA, Yu H, et al. FIZZ2/RELM-β induction and role in
pulmonary fibrosis. J Immunol 2011; 187: 450–461.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression
data using real-time quantitative PCR and the 2(−Delta Delta C(T))
method. Methods 2001; 25: 402–408.
37. Ding L, Dolgachev V, Wu Z, et al. Essential role of stem cell
factor–c-Kit signalling pathway in bleomycin-induced pulmonary
fibrosis. J Pathol 2013; 230: 205–214.
38. Wong SH, Walker JA, Jolin HE, et al. Transcription factor RORα is
critical for nuocyte development. Nat Immunol 2012; 13: 229–236.
39. Yang Q, Saenz SA, Zlotoff DA, et al. Cutting edge: natural helper
cells derive from lymphoid progenitors. J Immunol 2011; 187:
5505–5509.
40. Huang Y, Mao K, Chen X, et al. S1P-dependent interorgan traffick-
ing of group 2 innate lymphoid cells supports host defense. Science
2018; 359: 114–119.
41. Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015;
517: 293–301.
42. Spits H, Cupedo T. Innate lymphoid cells: emerging insights in
development, lineage relationships, and function. Annu Rev Immunol
2012; 30: 647–675.
43. McKenzie ANJ, Spits H, Eberl G. Innate lymphoid cells in inflam-
mation and immunity. Immunity 2014; 41: 366–374.
44. Molofsky AB, Van Gool F, Liang HE, et al. Interleukin-33 and
interferon-gamma counter-regulate group 2 innate lymphoid cell acti-
vation during immune perturbation. Immunity 2015; 43: 161–174.
45. Rak GD, Osborne LC, Siracusa MC, et al. IL-33-dependent group
2 innate lymphoid cells promote cutaneous wound healing. J Invest
Dermatol 2016; 136: 487–496.
46. Lee JU, Chang HS, Lee HJ, et al. Upregulation of interleukin-33
and thymic stromal lymphopoietin levels in the lungs of idiopathic
pulmonary fibrosis. BMC Pulm Med 2017; 17: 39.
47. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International
ST2 Consensus Panel. Am J Cardiol 2015; 115: 3B–7B.
48. Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apop-
tosis and improves survival after experimental myocardial infarction
through ST2 signaling. Circ Heart Fail 2009; 2: 684–691.
49. Gao Q, Li Y, Pan X, et al. Lentivirus expressing soluble ST2
alleviates bleomycin-induced pulmonary fibrosis in mice. Int
Immunopharmacol 2016; 30: 188–193.
50. Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum
soluble ST2 protein upon acute exacerbation of idiopathic pulmonary
fibrosis. Chest 2003; 124: 1206–1214.
51. Xu J, Guardado J, Hoffman R, et al. IL33-mediated ILC2 activation
and neutrophil IL5 production in the lung response after severe
trauma: a reverse translation study from a human cohort to a mouse
trauma model. PLoS Med 2017; 14: e1002365.
52. Wohlfahrt T, Usherenko S, Englbrecht M, et al. Type 2 innate lym-
phoid cell counts are increased in patients with systemic sclerosis
Copyright © 2018 Pathological Society of Great Britain and Ireland. J Pathol 2018; 245: 399–409
Published by John Wiley & Sons, Ltd. www.pathsoc.org www.thejournalofpathology.com
ILC2s from bone marrow promote lung fibrosis 409
and correlate with the extent of fibrosis. Ann Rheum Dis 2016; 75:
623–626.
53. Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 ampli-
fies the polarization of alternatively activated macrophages that con-
tribute to airway inflammation. J Immunol 2009; 183: 6469–6477.
54. He R, Yin H, Yuan B, et al. IL-33 improves wound healing through
enhanced M2 macrophage polarization in diabetic mice. Mol
Immunol 2017; 90: 42–49.
55. Barlow JL, Peel S, Fox J, et al. IL-33 is more potent than IL-25
in provoking IL-13-producing nuocytes (type 2 innate lymphoid
cells) and airway contraction. J Allergy Clin Immunol 2013;
132: 933–941.
56. Barlow JL, Bellosi A, Hardman CS, et al. Innate IL-13-producing
nuocytes arise during allergic lung inflammation and contribute
to airways hyperreactivity. J Allergy Clin Immunol 2012; 129:
191–198.e4.
57. Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of
interleukin 1 receptor-related T1/ST2 does not affect T helper cell
type 2 development and its effector function. J Exp Med 1999; 190:
1541–1548.
58. Wieland CW, van der Windt GJ, Florquin S, et al. ST2 deficient
mice display a normal host defense against pulmonary infection with
Mycobacterium tuberculosis. Microbes Infect 2009; 11: 524–530.
59. Keller J, Catala-Lehnen P, Wintges K, et al. Transgenic
over-expression of interleukin-33 in osteoblasts results in decreased
osteoclastogenesis. Biochem Biophys Res Commun 2012; 417:
217–222.
60. Saranchova I, Han J, Zaman R, et al. Type 2 innate lymphocytes
actuate immunity against tumours and limit cancer metastasis. Sci
Rep 2018; 8: 2924.
61. de Kleer IM, Kool M, de Bruijn MJ, et al. Perinatal activation of the
interleukin-33 pathway promotes type 2 immunity in the developing
lung. Immunity 2016; 45: 1285–1298.
62. Gasteiger G, Fan X, Dikiy S, et al. Tissue residency of innate lym-
phoid cells in lymphoid and nonlymphoid organs. Science 2015; 350:
981–985.
63. Saluzzo S, Gorki AD, Rana BMJ, et al. First-breath-induced type 2
pathways shape the lung immune environment. Cell Rep 2017; 18:
1893–1905.
64. Steer CA, Martinez-Gonzalez I, Ghaedi M, et al. Group 2 innate
lymphoid cell activation in the neonatal lung drives type 2 immu-
nity and allergen sensitization. J Allergy Clin Immunol 2017; 140:
593–595.e3.
65. Denney L, Byrne AJ, Shea TJ, et al. Pulmonary epithelial
cell-derived cytokine TGF-β1 is a critical cofactor for enhanced
innate lymphoid cell function. Immunity 2015; 43: 945–958.
66. Cutroneo KR, Phan SH. TGF-β1-induced Smad 3 binding to the
Smad 7 gene: knockout of Smad 7 gene transcription by sense phos-
phorothioate oligos, autoregulation, and effect on TGF-β1 secretion:
bleomycin acts through TGF-β1. J Cell Biochem 2003; 89: 474–483.
SUPPLEMENTARY MATERIAL ONLINE
Figure S1. BLM-induced pulmonary fibrosis was abrogated in ST2 KO BM chimera mice
Copyright © 2018 Pathological Society of Great Britain and Ireland. J Pathol 2018; 245: 399–409
Published by John Wiley & Sons, Ltd. www.pathsoc.org www.thejournalofpathology.com
